Afua Akhi-Gbade, MD
Family Medicine · Hiram, GANPI 1811343114
Payments from drug & device makers
Across 233 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$681
- Amgen$384
- Boehringer Ingelheim$292
- AbbVie$251
- Lilly USA, LLC$247
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$212
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,987100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $681 |
| Amgen | 24 | $384 |
| Boehringer Ingelheim | 17 | $292 |
| AbbVie | 16 | $251 |
| Lilly USA, LLC | 15 | $247 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $212 |
| Astellas Pharma US Inc | 9 | $183 |
| Sanofi-aventis U.S. LLC | 8 | $182 |
| Otsuka America Pharmaceutical, Inc. | 7 | $153 |
| GSK | 9 | $139 |
| Shield Therapeutics Inc | 6 | $123 |
| Abbott | 7 | $117 |
| Sumitomo Pharma America, Inc. | 8 | $108 |
| AstraZeneca | 7 | $97 |
| Dynavax Technologies Corporation | 4 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $77 |
| Dexcom, Inc. | 4 | $77 |
| Pfizer | 4 | $70 |
| Exact Sciences | 5 | $68 |
| Bayer | 3 | $51 |
| Daiichi Sankyo Inc. | 3 | $51 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Johnson & Johnson | 2 | $48 |
| Novartis | 2 | $47 |
| Merck | 2 | $44 |
| Lundbeck LLC | 1 | $33 |
| Bausch Health US, LLC | 1 | $24 |
| Boston Scientific | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Nevro Corp. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$3,987 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $73,252 |
| EliquisApixaban | 58 | $63,005 |
| JardianceEmpagliflozin | 43 | $59,218 |
| MounjaroTirzepatide | 45 | $55,223 |
| JanuviaSitagliptin Phosphate | 38 | $46,863 |
| FarxigaDapagliflozin Propanediol | 36 | $38,819 |
| XifaxanRifaximin | 11 | $35,607 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $35,460 |
| LinzessLinaclotide | 11 | $14,101 |
| VascepaIcosapent Ethyl | 26 | $14,082 |
| MyrbetriqMirabegron | 18 | $10,272 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,526 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $6,388 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,413 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 180 | $5,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $681 | $73,25256 claims |
| PfizerEliquis | $70 | $63,00558 claims |
| Boehringer IngelheimJardiance | $292 | $59,21843 claims |
| Lilly USA, LLCMounjaro | $247 | $55,22345 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Shingrix | $139 | $47,79883 claims |
| MerckJanuvia | $44 | $46,86338 claims |
| AstraZenecaFarxiga | $97 | $38,81936 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $212 | $35,60711 claims |
| AbbVieLinzess, Namzaric, Synthroid | $251 | $22,68850 claims |
| Astellas Pharma US IncMyrbetriq | $183 | $10,27218 claims |
| Sanofi-aventis U.S. LLCLantus | $182 | $3,80912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Hiram
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.